Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 5740373, 12 pages
http://dx.doi.org/10.1155/2016/5740373
Review Article

Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination

1Department of Internal Medicine, Division of Hematology, Maastricht University Medical Centre+, P.O. Box 616, 6200 MD Maastricht, Netherlands
2Tissue Typing Laboratory, Department of Transplantation Immunology, Maastricht University Medical Centre+, P.O. Box 616, 6200 MD Maastricht, Netherlands

Received 16 October 2015; Accepted 30 December 2015

Academic Editor: Evelien Smits

Copyright © 2016 Tammy Oth et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Kalantari, E. Kamali-Sarvestani, B. Ciric et al., “Generation of immunogenic and tolerogenic clinical-grade dendritic cells,” Immunologic Research, vol. 51, no. 2-3, pp. 153–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J.-C. Gluckman, B. Canque, and M. Rosenzwajg, “Dendritic cells: a complex simplicity,” Transplantation, vol. 73, no. 1, pp. S3–S6, 2002. View at Google Scholar · View at Scopus
  3. S. G. Reed, M. T. Orr, and C. B. Fox, “Key roles of adjuvants in modern vaccines,” Nature Medicine, vol. 19, no. 12, pp. 1597–1608, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. R. L. Coffman, A. Sher, and R. A. Seder, “Vaccine adjuvants: putting innate immunity to work,” Immunity, vol. 33, no. 4, pp. 492–503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Sallusto and A. Lanzavecchia, “Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α,” The Journal of Experimental Medicine, vol. 179, no. 4, pp. 1109–1118, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Schreibelt, J. Tel, K. H. E. W. J. Sliepen et al., “Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy,” Cancer Immunology, Immunotherapy, vol. 59, no. 10, pp. 1573–1582, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. H. M. J. Van Elssen, J. Vanderlocht, P. W. H. Frings et al., “Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells,” European Journal of Immunology, vol. 40, no. 11, pp. 3138–3149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. G. M. J. Bos, W. T. V. Germeraad, T. Oth, B. L. M. G. Senden Gijsbers, and J. Vanderlocht, “Method for the in vitro maturation of dendritic cells,” European Patent Application number EP13720885.6, 2012.
  9. M. P. Longhi, C. Trumpfheller, J. Idoyaga et al., “Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant,” Journal of Experimental Medicine, vol. 206, no. 7, pp. 1589–1602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Trumpfheller, M. Caskey, G. Nchinda et al., “The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2574–2579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Warger, P. Osterloh, G. Rechtsteiner et al., “Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo,” Blood, vol. 108, no. 2, pp. 544–550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Bourgeois and C. Tanchot, “CD4 T cells are required for CD8 T cell memory generation,” European Journal of Immunology, vol. 33, no. 12, pp. 3225–3231, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. A. H. Banday, S. Jeelani, and V. J. Hruby, “Cancer vaccine adjuvants—recent clinical progress and future perspectives,” Immunopharmacology and Immunotoxicology, vol. 37, no. 1, pp. 1–11, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Hajjar, R. K. Ernst, J. H. Tsai, C. B. Wilson, and S. I. Miller, “Human Toll-like receptor 4 recognizes host-specific LPS modifications,” Nature Immunology, vol. 3, no. 4, pp. 354–359, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Mestas and C. C. W. Hughes, “Of mice and not men: differences between mouse and human immunology,” Journal of Immunology, vol. 172, no. 5, pp. 2731–2738, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Oth, M. C. A. Schnijderberg, B. L. M. G. Senden-Gijsbers, W. T. V. Germeraad, G. M. J. Bos, and J. Vanderlocht, “Monitoring the initiation and kinetics of human dendritic cell-induced polarization of autologous naive CD4+ T cells,” PLoS ONE, vol. 9, no. 8, Article ID e103725, 2014. View at Publisher · View at Google Scholar
  17. T. Oth, C. H. M. J. Van Elssen, M. C. A. Schnijderberg, W. T. V. Germeraad, G. M. J. Bos, and J. Vanderlocht, “Human Th1 and NK helper cell activation are both determined by DC-derived IL-12p70, independent of the type of maturation stimuli,” Journal of Interferon & Cytokine Research, vol. 35, no. 9, pp. 748–758, 2015. View at Google Scholar
  18. R. B. Mailliard, S. M. Alber, H. Shen et al., “IL-18-induced CD83+CCR7+ NK helper cells,” The Journal of Experimental Medicine, vol. 202, no. 7, pp. 941–953, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. J. D. Miller, R. G. van der Most, R. S. Akondy et al., “Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines,” Immunity, vol. 28, no. 5, pp. 710–722, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. P. C. da Costa Neves, D. C. de Souza Matos, R. Marcovistz, and R. Galler, “TLR expression and NK cell activation after human yellow fever vaccination,” Vaccine, vol. 27, no. 41, pp. 5543–5549, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Kaczanowska, A. M. Joseph, and E. Davila, “TLR agonists: our best frenemy in cancer immunotherapy,” Journal of Leukocyte Biology, vol. 93, no. 6, pp. 847–863, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. D. M. R. Lathers, J. I. Clark, N. J. Achille, and M. R. I. Young, “Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamm D3,” Cancer Immunology, Immunotherapy, vol. 53, no. 5, pp. 422–430, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. O. Joffre, M. A. Nolte, R. Spörri, and C. Reis e Sousa, “Inflammatory signals in dendritic cell activation and the induction of adaptive immunity,” Immunological Reviews, vol. 227, no. 1, pp. 234–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Spörri and C. Reis e Sousa, “Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function,” Nature Immunology, vol. 6, no. 2, pp. 163–170, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Vanderlocht, C. H. M. J. Van Elssen, B. L. M. G. Senden-Gijsbers et al., “Increased tumor-specific CD8+ T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-gamma,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 1, pp. 35–50, 2010. View at Google Scholar · View at Scopus
  26. B. Hou, B. Reizis, and A. L. DeFranco, “Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms,” Immunity, vol. 29, no. 2, pp. 272–282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. F. J. Hsu, C. Benike, F. Fagnoni et al., “Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells,” Nature Medicine, vol. 2, no. 1, pp. 52–58, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. P. H. Patel and D. R. Kockler, “Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer,” Annals of Pharmacotherapy, vol. 42, no. 1, pp. 91–98, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Schlom, P. M. Arlen, and J. L. Gulley, “Cancer vaccines: moving beyond current paradigms,” Clinical Cancer Research, vol. 13, no. 13, pp. 3776–3782, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Schlom, J. L. Gulley, and P. M. Arlen, “Paradigm shifts in cancer vaccine therapy,” Experimental Biology and Medicine, vol. 233, no. 5, pp. 522–534, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. P. K. Srivastava, “Therapeutic cancer vaccines,” Current Opinion in Immunology, vol. 18, no. 2, pp. 201–205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. R. M. Steinman, “Dendritic cells in vivo: a key target for a new vaccine science,” Immunity, vol. 29, no. 3, pp. 319–324, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Schuler, B. Schuler-Thurner, and R. M. Steinman, “The use of dendritic cells in cancer immunotherapy,” Current Opinion in Immunology, vol. 15, no. 2, pp. 138–147, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Kaliński, C. M. U. Hilkens, E. A. Wierenga, and M. L. Kapsenberg, “T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal,” Immunology Today, vol. 20, no. 12, pp. 561–567, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Ikeda, K. Chamoto, T. Tsuji et al., “The critical role of type-1 innate and acquired immunity in tumor immunotherapy,” Cancer Science, vol. 95, no. 9, pp. 697–703, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Trinchieri, “Interleukin-12 and the regulation of innate resistance and adaptive immunity,” Nature Reviews Immunology, vol. 3, no. 2, pp. 133–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Pulendran, “Modulating Th1/Th2 responses with microbes, dendritic cells, and pathogen recognition receptors,” Immunologic Research, vol. 29, no. 1–3, pp. 187–196, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. B. J. Czerniecki, P. A. Cohen, M. Faries, S. Xu, J. G. Roros, and I. Bedrosian, “Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines,” Critical Reviews in Immunology, vol. 21, no. 1–3, pp. 157–178, 2001. View at Google Scholar · View at Scopus
  40. G. Ferlazzo, M. Pack, D. Thomas et al., “Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 47, pp. 16606–16611, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Kalinski and H. Okada, “Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors,” Seminars in Immunology, vol. 22, no. 3, pp. 173–182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Jeannin, T. Renno, L. Goetsch et al., “OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway,” Nature Immunology, vol. 1, no. 6, pp. 502–509, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. C. H. M. J. Van Elssen, T. Oth, W. T. V. Germeraad, G. M. J. Bos, and J. Vanderlocht, “Natural killer cells: the secret weapon in dendritic cell vaccination strategies,” Clinical Cancer Research, vol. 20, no. 5, pp. 1095–1103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Adams, “Toll-like receptor agonists in cancer therapy,” Immunotherapy, vol. 1, no. 6, pp. 949–964, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. S. F. Wolf, P. A. Temple, M. Kobayashi et al., “Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells,” The Journal of Immunology, vol. 146, no. 9, pp. 3074–3081, 1991. View at Google Scholar · View at Scopus
  46. V. Athie-Morales, H. H. Smits, D. A. Cantrell, and C. M. U. Hilkens, “Sustained IL-12 signaling is required for Th1 development,” The Journal of Immunology, vol. 172, no. 1, pp. 61–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. A. M. Dohnal, R. Luger, P. Paul, D. Fuchs, and T. Felzmann, “CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 1741–1750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. B. M. Carreno, M. Becker-Hapak, A. Huang et al., “IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity,” The Journal of Clinical Investigation, vol. 123, no. 8, pp. 3383–3394, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Okada, P. Kalinski, R. Ueda et al., “Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma,” Journal of Clinical Oncology, vol. 29, no. 3, pp. 330–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. M. B. Atkins, M. J. Robertson, M. Gordon et al., “Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies,” Clinical Cancer Research, vol. 3, no. 3, pp. 409–417, 1997. View at Google Scholar · View at Scopus
  51. J. P. Leonard, M. L. Sherman, G. L. Fisher et al., “Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production,” Blood, vol. 90, no. 7, pp. 2541–2548, 1997. View at Google Scholar · View at Scopus
  52. O. Hamid, J. C. Solomon, R. Scotland et al., “Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease,” Clinical Cancer Research, vol. 13, no. 1, pp. 215–222, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. A. C. Peterson, H. Harlin, and T. F. Gajewski, “Immunization with melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma,” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2342–2348, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. P. Colombo and G. Trinchieri, “Interleukin-12 in anti-tumor immunity and immunotherapy,” Cytokine and Growth Factor Reviews, vol. 13, no. 2, pp. 155–168, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Del Vecchio, E. Bajetta, S. Canova et al., “Interleukin-12: biological properties and clinical application,” Clinical Cancer Research, vol. 13, no. 16, pp. 4677–4685, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Anguille, E. L. Smits, E. Lion, V. F. van Tendeloo, and Z. N. Berneman, “Clinical use of dendritic cells for cancer therapy,” The Lancet Oncology, vol. 15, no. 7, pp. e257–e267, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. C. H. M. J. Van Elssen, J. Vanderlocht, T. Oth, B. L. M. G. Senden-Gijsbers, W. T. V. Germeraad, and G. M. J. Bos, “Inflammation restraining effects of prostaglandin E2 on natural killer–dendritic cell (NK-DC) interaction are imprinted during DC maturation,” Blood, vol. 118, no. 9, pp. 2473–2482, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Vitale, M. Della Chiesa, S. Carlomagno et al., “NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor,” Blood, vol. 106, no. 2, pp. 566–571, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Napolitani, A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia, “Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells,” Nature Immunology, vol. 6, no. 8, pp. 769–776, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Goyvaerts, K. Broos, D. Escors et al., “The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome,” European Journal of Immunology, vol. 45, no. 12, pp. 3351–3361, 2015. View at Publisher · View at Google Scholar
  61. M. Kreutz, G. Bakdash, Y. Dolen et al., “Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists,” European Journal of Immunology, vol. 45, no. 10, pp. 2798–2809, 2015. View at Publisher · View at Google Scholar
  62. S. S. Jensen and M. Gad, “Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity,” Journal of Inflammation, vol. 7, article 37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Langenkamp, M. Messi, A. Lanzavecchia, and F. Sallusto, “Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells,” Nature Immunology, vol. 1, no. 4, pp. 311–316, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. P. L. Vieira, E. C. de Jong, E. A. Wierenga, M. L. Kapsenberg, and P. Kaliński, “Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction,” The Journal of Immunology, vol. 164, no. 9, pp. 4507–4512, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Luger, S. Valookaran, N. Knapp, C. Vizzardelli, A. M. Dohnal, and T. Felzmann, “Toll-like receptor 4 engagement drives differentiation of human and murine dendritic cells from a pro- into an anti-inflammatory mode,” PLoS ONE, vol. 8, no. 2, Article ID e54879, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. A. M. Dohnal, S. Graffi, V. Witt et al., “Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines,” Journal of Cellular and Molecular Medicine, vol. 13, no. 1, pp. 125–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. V. Yilmaz, S. P. Yentür, and G. Saruhan-Direskeneli, “IL-12 and IL-10 polymorphisms and their effects on cytokine production,” Cytokine, vol. 30, no. 4, pp. 188–194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Seegers, A. Zwiers, W. Strober, A. S. Peña, and G. Bouma, “A TaqI polymorphism in the 3′ UTR of the IL-12 p40 gene correlates with increased IL-12 secretion,” Genes and Immunity, vol. 3, no. 7, pp. 419–423, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Müller-Berghaus, K. Kern, A. Paschen et al., “Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype,” Genes and Immunity, vol. 5, no. 5, pp. 431–434, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. J. C. Peng, S. Abu Bakar, M. M. Richardson et al., “IL10 and IL12B polymorphisms each influence IL-12p70 secretion by dendritic cells in response to LPS,” Immunology and Cell Biology, vol. 84, no. 2, pp. 227–232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. V. F. I. Van Tendeloo, P. Ponsaerts, and Z. N. Berneman, “mRNA-based gene transfer as a tool for gene and cell therapy,” Current Opinion in Molecular Therapeutics, vol. 9, no. 5, pp. 423–431, 2007. View at Google Scholar · View at Scopus
  72. E. L. J. M. Smits, S. Anguille, N. Cools, Z. N. Berneman, and V. F. I. Van Tendeloo, “Dendritic cell-based cancer gene therapy,” Human Gene Therapy, vol. 20, no. 10, pp. 1106–1118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Wilgenhof, J. Corthals, A. M. T. Van Nuffel et al., “Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases,” Cancer Immunology, Immunotherapy, vol. 64, pp. 381–388, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. M. W. Lipscomb, L. Chen, J. L. Taylor et al., “Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro,” Journal of Immunology, vol. 183, no. 11, pp. 7250–7258, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Qu, L. Chen, D. B. Lowe, W. J. Storkus, and J. L. Taylor, “Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo,” Molecular Therapy, vol. 20, no. 3, pp. 644–651, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. J. E. Boudreau, A. Bonehill, K. Thielemans, and Y. Wan, “Engineering dendritic cells to enhance cancer immunotherapy,” Molecular Therapy, vol. 19, no. 5, pp. 841–853, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Berk and P. Kalinski, “Lymphocyte-polarized DC1s: effective inducers of tumor-specific CTLs,” OncoImmunology, vol. 1, no. 8, pp. 1443–1444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Berk, R. Muthuswamy, and P. Kalinski, “Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs,” Vaccine, vol. 30, no. 43, pp. 6216–6224, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Lucas, N. Ghilardi, J. Li, and F. J. de Sauvage, “IL-27 regulates IL-12 responsiveness of naïve CD4+ T cells through Stat1-dependent and -independent mechanisms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15047–15052, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Tominaga, T. Yoshimoto, K. Torigoe et al., “IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells,” International Immunology, vol. 12, no. 2, pp. 151–160, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. J. L. Wong, E. Berk, R. P. Edwards, and P. Kalinski, “IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment,” Cancer Research, vol. 73, no. 15, pp. 4653–4662, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. R. B. Mailliard, Y.-I. Son, R. Redlinger et al., “Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function,” Journal of Immunology, vol. 171, no. 5, pp. 2366–2373, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. E. Mortier, T. Woo, R. Advincula, S. Gozalo, and A. Ma, “IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation,” The Journal of Experimental Medicine, vol. 205, no. 5, pp. 1213–1225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Vujanovic, D. E. Szymkowski, S. Alber, S. C. Watkins, N. L. Vujanovic, and L. H. Butterfield, “Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15,” Blood, vol. 116, no. 4, pp. 575–583, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Filipazzi, L. Pilla, L. Mariani et al., “Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides,” Clinical Cancer Research, vol. 18, no. 23, pp. 6485–6496, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. R. Bos and L. A. Sherman, “CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes,” Cancer Research, vol. 70, no. 21, pp. 8368–8377, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. S. B. J. Wong, R. Bos, and L. A. Sherman, “Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells,” Journal of Immunology, vol. 180, no. 5, pp. 3122–3131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Kreiter, M. Vormehr, N. van de Roemer et al., “Mutant MHC class II epitopes drive therapeutic immune responses to cancer,” Nature, vol. 520, no. 7549, pp. 692–696, 2015. View at Publisher · View at Google Scholar
  89. E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini, “Functions of natural killer cells,” Nature Immunology, vol. 9, no. 5, pp. 503–510, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. E. Vivier, D. H. Raulet, A. Moretta et al., “Innate or adaptive immunity? The example of natural killer cells,” Science, vol. 331, no. 6013, pp. 44–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Kalinski, A. Giermasz, Y. Nakamura et al., “Helper role of NK cells during the induction of anticancer responses by dendritic cells,” Molecular Immunology, vol. 42, no. 4, pp. 535–539, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Imai, S. Matsuyama, S. Miyake, K. Suga, and K. Nakachi, “Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population,” The Lancet, vol. 356, no. 9244, pp. 1795–1799, 2000. View at Publisher · View at Google Scholar · View at Scopus
  93. E. Lion, E. L. J. M. Smits, Z. N. Berneman, and V. F. I. Van Tendeloo, “NK cells: key to success of DC-based cancer vaccines?” Oncologist, vol. 17, no. 10, pp. 1256–1270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. L. Senovilla, E. Vacchelli, J. Galon et al., “Trial watch: prognostic and predictive value of the immune infiltrate in cancer,” OncoImmunology, vol. 1, no. 8, pp. 1323–1343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. M. R. Türkseven and T. Oygür, “Evaluation of natural killer cell defense in oral squamous cell carcinoma,” Oral Oncology, vol. 46, no. 5, pp. e34–e37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Ishigami, S. Natsugoe, K. Tokuda et al., “Prognostic value of intratumoral natural killer cells in gastric carcinoma,” Cancer, vol. 88, no. 3, pp. 577–583, 2000. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Cai, Z. Zhang, L. Zhou et al., “Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients,” Clinical Immunology, vol. 129, no. 3, pp. 428–437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. P. Carrega, B. Morandi, R. Costa et al., “Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56bright CD16- cells and display an impaired capability to kill tumor cells,” Cancer, vol. 112, no. 4, pp. 863–875, 2008. View at Publisher · View at Google Scholar
  99. G. Esendagli, K. Bruderek, T. Goldmann et al., “Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer,” Lung Cancer, vol. 59, no. 1, pp. 32–40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Fauriat, S. Just-Landi, F. Mallet et al., “Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction,” Blood, vol. 109, no. 1, pp. 323–330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. J. L. Wong, R. B. Mailliard, S. J. Moschos et al., “Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells,” Journal of Immunotherapy, vol. 34, no. 3, pp. 270–278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. J. J. P. van Beek, F. Wimmers, S. V. Hato, I. J. M. de Vries, and A. E. Sköld, “Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination,” Critical Reviews in Immunology, vol. 34, no. 6, pp. 517–536, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. K. Gustafsson, M. Ingelsten, L. Bergqvist, J. Nyström, B. Andersson, and A. Karlsson-Parra, “Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine,” Cancer Research, vol. 68, no. 14, pp. 5965–5971, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Gustafsson, K. Junevik, O. Werlenius, S. Holmgren, A. Karlsson-Parra, and P.-O. Andersson, “Tumour-loaded α-type 1-polarized Dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile,” Scandinavian Journal of Immunology, vol. 74, no. 3, pp. 318–326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Jinushi, T. Takehara, T. Kanto et al., “Critical role of MHC class I-related chain A and B expression on IFN-α-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection,” Journal of Immunology, vol. 170, no. 3, pp. 1249–1256, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Anguille, E. L. J. M. Smits, N. Cools, H. Goossens, Z. N. Berneman, and V. F. I. Van Tendeloo, “Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties,” Journal of Translational Medicine, vol. 7, article 109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Y. Hardy, A. J. Kassianos, A. Vulink et al., “NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells,” Immunology and Cell Biology, vol. 87, no. 8, pp. 606–614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. R. B. Mailliard, A. Wankowicz-Kalinska, Q. Cai et al., “α-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity,” Cancer Research, vol. 64, no. 17, pp. 5934–5937, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. P. B. Watchmaker, E. Berk, R. Muthuswamy et al., “Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells,” The Journal of Immunology, vol. 184, no. 2, pp. 591–597, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. R. Muthuswamy, J. Mueller-Berghaus, U. Haberkorn, T. A. Reinhart, D. Schadendorf, and P. Kalinski, “PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells,” Blood, vol. 116, no. 9, pp. 1454–1459, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Goc, C. Germain, T. K. D. Vo-Bourgais et al., “Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells,” Cancer Research, vol. 74, no. 3, pp. 705–715, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. A. Cipponi, M. Mercier, T. Seremet et al., “Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases,” Cancer Research, vol. 72, no. 16, pp. 3997–4007, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. Y. Nakanishi, B. Lu, C. Gerard, and A. Iwasaki, “CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help,” Nature, vol. 462, no. 7272, pp. 510–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. C. Kurts, B. W. S. Robinson, and P. A. Knolle, “Cross-priming in health and disease,” Nature Reviews Immunology, vol. 10, no. 6, pp. 403–414, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. F. Castellino, A. Y. Huang, G. Altan-Bonnet, S. Stoll, C. Scheinecker, and R. N. Germain, “Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction,” Nature, vol. 440, no. 7086, pp. 890–895, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. D. Sarhan, M. Palma, Y. Mao et al., “Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β,” European Journal of Immunology, vol. 45, no. 6, pp. 1783–1793, 2015. View at Publisher · View at Google Scholar
  117. J. I. Mayordomo, T. Zorina, W. J. Storkus et al., “Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity,” Nature Medicine, vol. 1, no. 12, pp. 1297–1302, 1995. View at Publisher · View at Google Scholar · View at Scopus
  118. R. E. M. Toes, E. I. H. Van der Voort, S. P. Schoenberger et al., “Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells,” The Journal of Immunology, vol. 160, no. 9, pp. 4449–4456, 1998. View at Google Scholar · View at Scopus
  119. J. A. Keene and J. Forman, “Helper activity is required for the in vivo generation of cytotoxic T lymphocytes,” Journal of Experimental Medicine, vol. 155, no. 3, pp. 768–782, 1982. View at Publisher · View at Google Scholar · View at Scopus
  120. S. R. M. Bennett, F. R. Carbone, F. Karamalis, J. F. A. P. Miller, and W. R. Heath, “Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help,” Journal of Experimental Medicine, vol. 186, no. 1, pp. 65–70, 1997. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Adam, S. King, T. Allgeier et al., “DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction,” Blood, vol. 106, no. 1, pp. 338–344, 2005. View at Publisher · View at Google Scholar · View at Scopus
  122. R. Weth, O. Christ, S. Stevanovic, and M. Zöller, “Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination,” Cancer Gene Therapy, vol. 8, no. 8, pp. 599–611, 2001. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Bonehill, C. Heirman, S. Tuyaerts et al., “Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules,” Journal of Immunology, vol. 172, no. 11, pp. 6649–6657, 2004. View at Publisher · View at Google Scholar · View at Scopus
  124. Y. Huang, F.-M. Wang, T. Wang et al., “Tumor-infiltrating FoxP3+ tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients,” Digestion, vol. 86, no. 4, pp. 329–337, 2013. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Pedroza-Gonzalez, C. Verhoef, J. N. M. Ijzermans et al., “Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer,” Hepatology, vol. 57, no. 1, pp. 183–194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. N. A. Giraldo, E. Becht, R. Remark, D. Damotte, C. Sautès-Fridman, and W. H. Fridman, “The immune contexture of primary and metastatic human tumours,” Current Opinion in Immunology, vol. 27, no. 1, pp. 8–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Galon, W.-H. Fridman, and F. Pages, “The adaptive immunologic microenvironment in colorectal cancer: a novel perspective,” Cancer Research, vol. 67, no. 5, pp. 1883–1886, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. J. Galon, F. Pagès, F. M. Marincola et al., “Cancer classification using the immunoscore: a worldwide task force,” Journal of Translational Medicine, vol. 10, article 205, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Gerlinger, A. J. Rowan, S. Horswell et al., “Intratumor heterogeneity and branched evolution revealed by multiregion sequencing,” The New England Journal of Medicine, vol. 366, no. 10, pp. 883–892, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Greaves and C. C. Maley, “Clonal evolution in cancer,” Nature, vol. 481, no. 7381, pp. 306–313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. L. M. F. Merlo, J. W. Pepper, B. J. Reid, and C. C. Maley, “Cancer as an evolutionary and ecological process,” Nature Reviews Cancer, vol. 6, no. 12, pp. 924–935, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. J. G. van den Boorn and G. Hartmann, “Turning tumors into vaccines: co-opting the innate immune system,” Immunity, vol. 39, no. 1, pp. 27–37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. D. Hannani, M. Vétizou, D. Enot et al., “Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25,” Cell Research, vol. 25, no. 2, pp. 208–224, 2015. View at Publisher · View at Google Scholar
  135. K. M. Mahoney, P. D. Rennert, and G. J. Freeman, “Combination cancer immunotherapy and new immunomodulatory targets,” Nature Reviews Drug Discovery, vol. 14, no. 8, pp. 561–584, 2015. View at Publisher · View at Google Scholar
  136. J. B. Haanen, H. van Thienen, and C. U. Blank, “Toxicity patterns with immunomodulating antibodies and their combinations,” Seminars in Oncology, vol. 42, no. 3, pp. 423–428, 2015. View at Publisher · View at Google Scholar
  137. M. A. Williams and M. J. Bevan, “Effector and memory CTL differentiation,” Annual Review of Immunology, vol. 25, pp. 171–192, 2007. View at Publisher · View at Google Scholar · View at Scopus
  138. J. F. M. Jacobs, C. J. A. Punt, W. J. Lesterhuis et al., “Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients,” Clinical Cancer Research, vol. 16, no. 20, pp. 5067–5078, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. D. Sugiyama, H. Nishikawa, Y. Maeda et al., “Anti-CCR4 mAb selectively depletes effector-Type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 44, pp. 17945–17950, 2013. View at Publisher · View at Google Scholar · View at Scopus
  140. J. Shimizu, S. Yamazaki, T. Takahashi, Y. Ishida, and S. Sakaguchi, “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Nature Immunology, vol. 3, no. 2, pp. 135–142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  141. K. Ko, S. Yamazaki, K. Nakamura et al., “Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells,” Journal of Experimental Medicine, vol. 202, no. 7, pp. 885–891, 2005. View at Publisher · View at Google Scholar · View at Scopus
  142. J. Mitsui, H. Nishikawa, D. Muraoka et al., “Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals,” Clinical Cancer Research, vol. 16, no. 10, pp. 2781–2791, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. B. Valzasina, C. Guiducci, H. Dislich, N. Killeen, A. D. Weinberg, and M. P. Colombo, “Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR,” Blood, vol. 105, no. 7, pp. 2845–2851, 2005. View at Publisher · View at Google Scholar · View at Scopus
  144. S. Piconese, B. Valzasina, and M. P. Colombo, “OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection,” Journal of Experimental Medicine, vol. 205, no. 4, pp. 825–839, 2008. View at Publisher · View at Google Scholar · View at Scopus
  145. J. Galon, F. Pagès, F. M. Marincola et al., “Cancer classification using the immunoscore: a worldwide task force,” Journal of Translational Medicine, vol. 10, no. 1, article 205, 2012. View at Publisher · View at Google Scholar · View at Scopus
  146. F. Pagès, A. Kirilovsky, B. Mlecnik et al., “In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5944–5951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  147. R. A. Madan, M. Mohebtash, P. M. Arlen et al., “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” The Lancet Oncology, vol. 13, no. 5, pp. 501–508, 2012. View at Publisher · View at Google Scholar · View at Scopus
  148. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. S. L. Topalian, M. Sznol, D. F. McDermott et al., “Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab,” Journal of Clinical Oncology, vol. 32, no. 10, pp. 1020–1030, 2014. View at Publisher · View at Google Scholar · View at Scopus
  150. H. I. Cho, S. H. Jung, H. J. Sohn, E. Celis, and T. G. Kim, “An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects,” OncoImmunology, vol. 4, no. 11, Article ID e1043504, 2015. View at Publisher · View at Google Scholar